ArticleInternational journal of chronic obstructive pulmonary disease2025
Unveiling the Role of Cathepsins on Lung Function in Chronic Obstructive Pulmonary Disease: A Mendelian Randomization Analysis.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Proteolysis at the extracellular matrix interface: Molecular architects and regulators in health and disease.The FEBS journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Cathepsins are a group of proteases that can degrade the extracellular matrix of the lungs, leading to lung tissue destruction and remodeling in chronic obstructive pulmonary disease (COPD). However, the causal relationship between cathepsins and COPD remains unclear. Methods: We performed a two-sample Mendelian randomization (MR) analysis using genetic instruments for nine cathepsins (B, E, F, G, H, L2, O, S, and Z) and lung function measures (FVC, FEV1, FEV1/FVC, and PEF) in COPD. The MR analysis was conducted and reported as conducted and reported in accordance with the STROBE-MR Statement. We employed various MR methods and conducted sensitivity analyses to validate the results. Results: We found a significant association of cathepsin B with PEF (IVW beta = 0.016, 95% CI = 0.007 to 0.024, P = 2.83E-4), the FEV1/FVC ratio (IVW beta = 0.014, 95% CI = 0.004 to 0.023, P = 0.004), and FEV1 (IVW beta = 0.010, 95% CI = 0.002 to 0.018, P = 0.012) in COPD. These associations were consistent across different MR methods and robust to pleiotropy and heterogeneity. Multivariate MR analysis confirmed the independent effect of cathepsin B on lung function after adjusting for other cathepsins. Reverse MR analysis and colocalization analysis showed no evidence of reverse causality or shared genetic pathways with smoking. Conclusion: Our study suggested that elevated cathepsin B levels may reduce the risk of lung function decline in COPD. Targeting cathepsin B and its inhibitors could be a potential therapeutic strategy for COPD. Reduced serum levels of cathepsin B may serve as a biomarker of progressive decline in lung function in patients with COPD. However, further studies are needed to elucidate the underlying mechanisms and clinical implications of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.